No association of α1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients

Meredyth P. Bass, Larry H. Yamaoka, William K. Scott, P. Craig Gaskell, Kathleen A. Welsh-Bohmer, Allen D. Roses, Ann M. Saunders, Jonathan L. Haines, Margaret A. Pericak-Vance

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The α1-antichymotrypsin (AACT)-155 allale was found elsewhere to have a significant effect on Alzheimer disease (AD) risk in individuals with at least one APOE-4 allale. We compared AACT genotypes of 284 cases of sporadic AD and 172 controls. The frequency of the AACT-155 allele did not differ significantly between cases and controls, either overall or when restricted to subjects with at least one APOE-4 allale. Logistic regression controlling for age and sex failed to show an effect due to AACT either alone or acting with APOE. There was no evidence of an interaction between APOE-4 and the AACT-155 allale to reduce age at onset. Thus, our data do not support an association of AACT-155 with risk or age at onset in AD.

Original languageEnglish (US)
Pages (from-to)79-82
Number of pages4
JournalNeuroscience Letters
Volume250
Issue number2
DOIs
StatePublished - Jun 19 1998
Externally publishedYes

Keywords

  • Alzheimer disease
  • Association study
  • Candidate gene
  • Polymorphism
  • α-Antichymotrypsin

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'No association of α<sub>1</sub>-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients'. Together they form a unique fingerprint.

Cite this